HyperAcute(R)-Pancreatic Cancer Vaccine

BIOLOGICAL2 trials

Sponsors

NewLink Genetics Corporation

Conditions

Pancreatic Cancer

Phase 2

Vaccine Study for Surgically Resected Pancreatic Cancer

CompletedNCT00569387

NewLink Genetics CorporationPancreatic Cancer

Start: 2007-12-31End: 2014-12-31Updated: 2020-05-28

Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer

TerminatedNCT00614601

NewLink Genetics CorporationPancreatic Cancer

Start: 2008-01-31End: 2014-12-31Updated: 2020-05-28

Related Papers

Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer.

Journal of Clinical Oncology2014-05-208 citations

Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.

2012-11-15150 citations